Skip to Content

Ryzodeg 70/30 Approval History

  • FDA approved: Yes (First approved September 25th, 2015)
  • Brand name: Ryzodeg 70/30
  • Generic name: insulin degludec and insulin aspart
  • Dosage form: Injection
  • Company: Novo Nordisk
  • Treatment for: Diabetes, Type 1, Diabetes, Type 2

Ryzodeg 70/30 (insulin degludec and insulin aspart) is a long-acting insulin analog and rapid-acting human insulin analog combination indicated to improve glycemic control in adults with diabetes mellitus.

Development History and FDA Approval Process for Ryzodeg 70/30

Sep 25, 2015Approval FDA Approves Ryzodeg 70/30 (insulin degludec/insulin aspart) for Diabetes Mellitus

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.